Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › delamanid

delamanid

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of delamanid

6 trials tracked of delamanid.

6Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 5 Other / NA 1
  1. Phase 2 Treatment Shortening of MDR-TB Using Existing and New Drugs Completed
  2. Phase 2 A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB) Completed
  3. Phase 2 A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 Completed
  4. Phase 2 A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) Completed
  5. Phase 2 Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis Completed
  6. N/A Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
6-month bedaquiline, linezolid, delamanid, and levofloxacin or clofazimine regimen is noninferior to 9-month standard care
Infectious Disease RCT
6-month bedaquiline, linezolid, delamanid, and levofloxacin or clofazimine regimen is noninferior to 9-month standard care Trial shows shorter treatment works for resistant tuberculosis
This Phase 3 randomized controlled noninferiority trial evaluated a 6-month treatment strategy for pulmonary rifampicin-resistant tuberculos…
A new six-month treatment plan for drug-resistant tuberculosis showed similar success rates to the standard nine-month course.
Jun 25, 2026